Grande, E.Garcia-Carbonero, R.Teule, A.Benavent Vinuales, M.Jimenez-Fonseca, P.Molina-Cerrillo, J.Lopez, C.Custodio, A.Hierro, C.Gallego, J.Alonso, V.Carmona-Bayonas, A.Llanos, M.Sevilla, I.Hernando, J.Lista, F.Anton Pascual, B.Ruffinelli, J. C.Gallego Jimenez, I.Capdevila, J.2025-01-072025-01-072021-09-21Grande, E., Garcia-Carbonero, R.. Teule, A., Benavent Vinuales, M., Jimenez-Fonseca, P. , Molina-Cerrillo, J., et al . Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914). Annals of Oncology. Septiembre 2021 (32), S624 - S6250923-7534https://hdl.handle.net/10668/27029Antiangiogenic agents have demonstrated antitumor properties in endocrine malignancies regardless of their primary origin. Experience with immune-checkpoint inhibitors is limited in this area and early results when used as single agents are discouraging. The aim of this trial is to assess the efficacy and safety of the combination of cabozantinib and atezolizumab, which may overcome the resistance in previously treated metastatic endocrine tumors .encabozantinibEndocrine Gland NeoplasmsatezolizumabAngiogenesis InhibitorsImmune Checkpoint Inhibitorsconference outputRestricted AccessNeoplasmsEfficacyAngiogenesis InhibitorsSafety10.1016/j.annonc.2021.08.7101569-8041https://doi.org/10.1016/j.annonc.2021.08.710700527701039